Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in non-ambulatory Duchenne muscular dystrophy patients
CTR20212108Phase 3Terminated
- Sponsor
- FibroGen
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pamrevlumab in Duchenne muscular dystrophy (DMD), sponsored by FibroGen. Started Aug 2021; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on CTR20212108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212108.